Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

Biohaven Stock Hits 52-Week Low, Cuts R&D Spending After FDA Rejection

Biohaven Ltd. (NYSE:BHVN) stock plummeted on Wednesday, reaching its 52-week low, according to data from Benzinga Pro.

Benzinga

US ambassador warns pharma firms will quit UK if NHS does not pay more for drugs

Donald Trump’s man in London reiterated the US president’s demands for the UK to pay pharmaceutical companies more money.

Evening Standard

Druckenmiller's Viking Trade Just Hit A Golden Cross — And A Sweet 36% Gain

Stanley Druckenmiller's Viking Therapeutics Inc (NASDAQ:VKTX) bet is starting to look like a classic Druckenmiller move — quietly bold, impeccably timed, and now technically validated. The billionaire investor's family office took a fresh position in VKTX during the second quarter, buying roughly 549,000 shares at an average price of $25.33.…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pfizer, Novo Nordisk Locked in High-Stakes Fight Over Obesity Drug Innovator Metsera

Pfizer and Novo Nordisk are in a heated battle to acquire obesity drug developer Metsera, driving legal and market tension.

International Business Times

Ozempic Maker Novo Nordisk Trims Growth Outlook For Obesity Drugs

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported third-quarter 2025 sales of roughly $11.75 billion (74.98 billion Danish kroner), slightly below the consensus of $11.88 billion.

Benzinga

Ozempic maker struggles as it loses ground to rivals in weight-loss market

Novo Nordisk cuts sales and profit forecasts as it continues to lose ground to Mounjaro firm Eli Lilly

The Guardian - UK

Cryoport Reports Strong Q3 Results, Raises FY25 Outlook

Cryoport Inc (NASDAQ:CYRX) reported third-quarter financial results after the market close on Tuesday. Here’s a rundown of the temperature-controlled supply chain solutions company’s report.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It

Pfizer Inc's (NYSE:PFE) lawsuit. Novo Nordisk A/S' (NYSE:NVO) counterbid. And in the middle of it all — a quiet $45 million position that might turn into Andreas Halvorsen's next masterstroke. After years of fighting from the sidelines of the Ozempic boom, Pfizer is finally throwing punches.

Benzinga

Chaos at the FDA leaves staffers disturbed, ready to leave

Questions over reliability have risen over the underperforming and dysfunctional FDA.

Axios

What's Up With The Rise In Eli Lilly Stock Today?

Eli Lilly and Company (NYSE:LLY) shares are trading higher on Monday. The pharmaceutical giant announced a significant European manufacturing expansion for oral medicine.

Benzinga

AMD hit with lawsuit over hybrid bonding tech behind potent 3D V-Cache — Adeia claims company's gaming chip infringes 10 of its patents

Adeia has filed a pair of patent infringement lawsuits against AMD in the U.S. District Court for the Western District of Texas, accusing the chipmaker of using its hybrid bonding and advanced node technologies without permission.

Tom’s Hardware

Time for Reeves to recognise reality: AstraZeneca has killed stamp duty on shares

Shareholder-backed plans to upgrade US listing have exposed multiple flaws in tax that should be abolished or at least cut

The Guardian - UK

Palantir Q3 Preview: 'AI Juggernaut' Can Double Market Cap To $1 Trillion, Analyst Says

Palantir Technologies Inc (NASDQ:PLTR) reports third-quarter financial results on Monday after market close, with shares trading at all-time highs.

Benzinga

Biotech ETFs Come Alive As Illumina Soars 23% — Is The Genomics Winter Finally Over?

Biotech investors finally got a dose of good news this week. Illumina Inc (NASDAQ:ILMN) staged a powerful comeback, with the stock surging over 23% on Friday after topping its third-quarter guidance while narrowing its full-year revenue decline forecast. Now, the rally of this genomics firm has rippled through the ETF…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

FDA Drug Chief George Tidmarsh Resigns After Allegations Of Power Misuse

George Tidmarsh, head of the Food and Drug Administration’s (FDA) drug center, resigned Sunday following allegations that he misused his regulatory power to financially harm a former business associate.

International Business Times

Pfizer Sues Rivals Metsera, Novo Nordisk Over Alleged Interference in Merger Talks

Pfizer sues Metsera and Novo Nordisk to block a rival bid in a high-stakes obesity drug merger.

Benzinga

Eli Lilly Seen In 'Pole Position' For Growth, Analysts Say

Eli Lilly and Co. (NYSE:LLY) reported better-than-expected third-quarter earnings on Thursday and boosted its annual forecast, sending the stock higher.

Benzinga

Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026

Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

DNA Sequencing Firm Illumina Sees Strong Clinical Market Momentum, Stock Soars

Illumina Inc. (NASDAQ:ILMN) stock is trading higher after the company reported better-than-expected third-quarter earnings.

Benzinga

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

AbbVie Inc. (NYSE:ABBV) reported third-quarter 2025 sales of $15.78 billion on Friday, beating the consensus of $15.59 billion.

Benzinga

Baxter Trims Annual Outlook Again, Stock Hits 52-Week

Baxter International Inc. (NYSE:BAX) stock hit a 52-week low on Thursday, after the company again lowered its 2025 guidance.

Benzinga

Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast

Eli Lilly and Co. (NYSE:LLY) on Thursday reported better-than-expected third-quarter earnings and boosted its annual forecast, sending the stock higher.

International Business Times

New Walmart Partnership to Let Patients Buy Eli Lilly's Zepbound Without Insurance Hassles

Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.

The Guardian - UK

‘Patients will suffer’: tales from the frontline of the UK pharma crisis

The pricing standoff between government and industry has stalled research and put thousands of jobs at risk

The Independent UK

Federal health officials push effort to spur cheaper biotech drugs

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend on to treat autoimmune diseases or cancers

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.